Jazz Pharmaceuticals plc News Releases http://investor.jazzpharma.com/ Jazz Pharmaceuticals plc News Releases en Jazz Pharmaceuticals Announces Webcast for Sunosi Investor Update http://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-webcast-sunosi-investor-update DUBLIN , June 25, 2019 /PRNewswire/ --  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Tuesday, July 2, 2019 at 4:30 p.m. EDT / 9:30 p.m. IST to provide investors with an update on Sunosi™ (solriamfetol), which was approved by the U.S. Tue, 25 Jun 2019 16:05:00 -0400 Jazz Pharmaceuticals plc News Releases 16351 Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi™ (solriamfetol) http://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-receives-schedule-iv-designation-dea Sunosi expected to be commercially available in the U.S. July 2019 Investor webcast planned for July 2, 2019 DUBLIN , June 17, 2019 /PRNewswire/ --  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Drug Enforcement Agency (DEA) has designated solriamfetol, also known as Sunosi Mon, 17 Jun 2019 08:00:00 -0400 Jazz Pharmaceuticals plc News Releases 16346 Jazz Pharmaceuticals Appoints Dr. Robert Iannone as Executive Vice President, Research and Development http://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-appoints-dr-robert-iannone-executive-vice-0 DUBLIN , June 3, 2019 /PRNewswire/ --  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Robert Iannone , M.D., M.S.C.E., as executive vice president, research and development, effective May 29, 2019 . Dr. Iannone will lead Jazz's growing global R&D organization, including Mon, 03 Jun 2019 08:00:00 -0400 Jazz Pharmaceuticals plc News Releases 16301 Jazz Pharmaceuticals to Present New Data at Upcoming ASCO Annual Meeting and EHA Congress http://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-present-new-data-upcoming-asco-annual Data to be presented underscore commitment to developing life-changing medicines in hematology/oncology for people with limited or no treatment options DUBLIN , May 16, 2019 /PRNewswire/ --  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that it will present data from across its Thu, 16 May 2019 16:30:00 -0400 Jazz Pharmaceuticals plc News Releases 16291 Jazz Pharmaceuticals Data to Showcase Ongoing Sleep Medicine Research at SLEEP 2019 http://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-data-showcase-ongoing-sleep-medicine Fourteen abstracts highlight Jazz's breadth in sleep medicine research and commitment to developing treatment options for people living with debilitating sleep disorders DUBLIN , May 9, 2019 /PRNewswire/ --  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that 14 abstracts sponsored by Jazz Thu, 09 May 2019 08:00:00 -0400 Jazz Pharmaceuticals plc News Releases 16286 Jazz Pharmaceuticals Announces First Quarter 2019 Financial Results http://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-first-quarter-2019-financial Total Revenues Increased 14% to $508 Million GAAP Diluted EPS of $1.47; Adjusted Diluted EPS of $3.67 Received FDA Approval of Sunosi for Excessive Daytime Sleepiness (EDS) Associated with Narcolepsy or Obstructive Sleep Apnea (OSA) Announced Positive Top-line Results from Phase 3 Study of JZP-258 Tue, 07 May 2019 16:05:00 -0400 Jazz Pharmaceuticals plc News Releases 16266 Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences http://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-participation-two-upcoming-2 DUBLIN , May 6, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences. Bank of America Merrill Lynch Healthcare Conference in Las Vegas on Tuesday, May 14, 2019 at 8:00 a.m. Mon, 06 May 2019 16:05:00 -0400 Jazz Pharmaceuticals plc News Releases 16241 Jazz Pharmaceuticals to Report 2019 First Quarter Financial Results on May 7, 2019 http://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-report-2019-first-quarter-financial-results DUBLIN , April 23, 2019 /PRNewswire/ --  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 first quarter financial results on Tuesday, May 7, 2019 , after the close of the financial markets.  Company management will host a live audio webcast immediately following Tue, 23 Apr 2019 16:05:00 -0400 Jazz Pharmaceuticals plc News Releases 16226 Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness http://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-positive-top-line-results-phase-3 JZP-258 achieves primary and key secondary endpoints demonstrating highly statistically significant differences in weekly number of cataplexy attacks and Epworth Sleepiness Scale scores compared to placebo DUBLIN , March 26, 2019 /PRNewswire/ --  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today Tue, 26 Mar 2019 16:13:00 -0400 Jazz Pharmaceuticals plc News Releases 16206 Jazz Pharmaceuticals Announces U.S. FDA Approval of Sunosi™ (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea http://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-us-fda-approval-sunositm Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor approved by the FDA to improve wakefulness in adults living with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea DUBLIN , March 20, 2019 /PRNewswire/ --  Jazz Pharmaceuticals Wed, 20 Mar 2019 18:53:00 -0400 Jazz Pharmaceuticals plc News Releases 16196